Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.56 +2.1%	$8.83	$6.01 ▼ $11.31	$1.80B	1.1	3.36 million shs	2.20 million shs
CLDX Celldex Therapeutics	$22.46 +2.0%	$22.12	$14.40 ▼ $47.00	$1.49B	1.22	1.31 million shs	1.80 million shs
MYGN Myriad Genetics	$6.02 +3.3%	$5.15	$3.76 ▼ $29.30	$560.13M	1.89	2.48 million shs	1.01 million shs
NVAX Novavax	$7.84 +2.8%	$7.30	$5.01 ▼ $15.22	$1.27B	2.5	8.43 million shs	8.46 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	+2.27%	+0.12%	-19.17%	+6.87%
CLDX Celldex Therapeutics	0.00%	-11.92%	-3.27%	+10.37%	-37.75%
MYGN Myriad Genetics	0.00%	+5.43%	+29.46%	+53.96%	-78.45%
NVAX Novavax	0.00%	-18.16%	+2.62%	+8.14%	-39.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.2021 of 5 stars	3.5	2.0	4.2	2.5	2.5	0.6
CLDX Celldex Therapeutics	1.6055 of 5 stars	3.4	3.0	0.0	1.7	0.0	0.0
MYGN Myriad Genetics	3.6162 of 5 stars	3.1	2.0	4.1	2.4	1.7	0.0
NVAX Novavax	4.6172 of 5 stars	3.1	2.0	4.7	3.0	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	95.09% Upside
CLDX Celldex Therapeutics	2.78	Moderate Buy	$46.67	107.78% Upside
MYGN Myriad Genetics	2.21	Hold	$12.45	106.89% Upside
NVAX Novavax	2.13	Hold	$15.57	98.62% Upside

Current Analyst Ratings Breakdown

Latest MYGN, BCRX, CLDX, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$44.00 ➝ $38.00
8/20/2025	CLDX Celldex Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$56.00 ➝ $48.00
8/20/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $62.00
8/20/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $42.00
8/20/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform	$9.00 ➝ $7.00
8/4/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/22/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	3.99	N/A	N/A	($2.01) per share	-4.26
CLDX Celldex Therapeutics	$7.02M	212.47	N/A	N/A	$9.87 per share	2.28
MYGN Myriad Genetics	$832.90M	0.67	$1.00 per share	6.03	$4.17 per share	1.44
NVAX Novavax	$1.08B	1.18	N/A	N/A	$0.23 per share	34.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.18	N/A	N/A	1.94	-6.41%	N/A	-1.78%	11/3/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$3.01	N/A	N/A	N/A	-3,446.88%	-27.61%	-26.20%	11/5/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	11/6/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.28	3.44	98.00	0.10	39.20%	-142.33%	28.65%	11/11/2025 (Estimated)

Latest MYGN, BCRX, CLDX, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	-$0.85	+$0.01	-$0.85	$1.13 million	$0.73 million
8/6/2025	Q2 2025	NVAX Novavax	-$0.07	$0.62	+$0.69	$0.62	$149.19 million	$239.24 million
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.03	$0.15	+$0.12	$0.02	$149.59 million	$163.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.25	2.22
CLDX Celldex Therapeutics	N/A	19.67	19.67
MYGN Myriad Genetics	N/A	1.42	1.28
NVAX Novavax	5.93	2.36	2.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CLDX Celldex Therapeutics	N/A
MYGN Myriad Genetics	99.02%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	5.10%
CLDX Celldex Therapeutics	4.40%
MYGN Myriad Genetics	2.40%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.92 million	199.21 million	Optionable
CLDX Celldex Therapeutics	150	66.41 million	63.49 million	Optionable
MYGN Myriad Genetics	2,700	93.05 million	90.81 million	Optionable
NVAX Novavax	1,990	162.42 million	160.80 million	Optionable

MYGN, BCRX, CLDX, and NVAX Headlines

Recent News About These Companies

Novavax (NVAX): How Debt Extension and Fresh Funding Shape Its Current Valuation

August 24 at 9:33 AM | finance.yahoo.com

Notable healthcare headlines for the week: Novo Nordisk, Medtronic, Novavax in focus

August 24 at 9:30 AM | seekingalpha.com

Novavax Faces Stock Slump Amid Downgrade

August 23 at 10:10 AM | tipranks.com

Novavax Shares Are Trading Higher Thursday: What's Going On?

August 22 at 4:36 PM | benzinga.com

What the Options Market Tells Us About Novavax

August 22 at 4:35 PM | benzinga.com

Bank of America Reiterates Underperform Rating for Novavax (NASDAQ:NVAX)

August 22 at 8:48 AM | marketbeat.com

Novavax Announces $225M Convertible Senior Notes Issuance

August 21 at 8:51 AM | tipranks.com

Novavax announces convertible debt refinancing

August 21 at 8:10 AM | seekingalpha.com

Novavax Announces Convertible Debt Refinancing

August 21 at 7:43 AM | prnewswire.com

Fox Run Management L.L.C. Invests $479,000 in Novavax, Inc. $NVAX

August 21 at 4:08 AM | marketbeat.com

B of A Securities Downgrades Novavax (NVAX)

August 20, 2025 | msn.com

Stock Traders Buy Large Volume of Novavax Call Options (NASDAQ:NVAX)

August 20, 2025 | marketbeat.com

BofA downgrades Novavax stock on vaccine uncertainty

August 20, 2025 | in.investing.com

Novavax downgraded to Underperform from Neutral at BofA

August 20, 2025 | msn.com

Nu double upgraded, Novavax downgraded: Wall Street's top analyst calls

August 20, 2025 | finance.yahoo.com

Novavax downgraded to Underperform at BofA on growth uncertainties

August 20, 2025 | msn.com

Novavax (NASDAQ:NVAX) Shares Gap Up - Should You Buy?

August 20, 2025 | marketbeat.com

Entropy Technologies LP Invests $191,000 in Novavax, Inc. (NASDAQ:NVAX)

August 18, 2025 | marketbeat.com

Novavax (NASDAQ:NVAX) Trading 5.4% Higher - Here's What Happened

August 16, 2025 | marketbeat.com

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

August 13, 2025 | zacks.com

Novavax (NASDAQ:NVAX) Trading Down 5.7% - Here's Why

August 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN, BCRX, CLDX, and NVAX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.56 +0.18 (+2.15%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.51 -0.05 (-0.63%)

As of 08/22/2025 07:57 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics NASDAQ:CLDX

$22.46 +0.44 (+2.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$22.78 +0.32 (+1.42%)

As of 08/22/2025 07:44 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Myriad Genetics NASDAQ:MYGN

$6.02 +0.19 (+3.26%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.00 -0.02 (-0.33%)

As of 08/22/2025 07:33 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Novavax NASDAQ:NVAX

$7.84 +0.21 (+2.75%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.88 +0.04 (+0.57%)

As of 08/22/2025 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time